182 related articles for article (PubMed ID: 32436013)
21. Abdominal-pelvic lymphoproliferative disease after lung transplantation: presentation and outcome.
Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
Transplantation; 2004 Feb; 77(3):431-7. PubMed ID: 14966421
[TBL] [Abstract][Full Text] [Related]
22. Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients.
Oyama T; Yamamoto K; Asano N; Oshiro A; Suzuki R; Kagami Y; Morishima Y; Takeuchi K; Izumo T; Mori S; Ohshima K; Suzumiya J; Nakamura N; Abe M; Ichimura K; Sato Y; Yoshino T; Naoe T; Shimoyama Y; Kamiya Y; Kinoshita T; Nakamura S
Clin Cancer Res; 2007 Sep; 13(17):5124-32. PubMed ID: 17785567
[TBL] [Abstract][Full Text] [Related]
23. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
[TBL] [Abstract][Full Text] [Related]
24. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection.
Hoshida Y; Tomita Y; Zhiming D; Yamauchi A; Nakatsuka S; Kurasono Y; Arima Y; Tsudo M; Shintaku M; Aozasa K
Int J Cancer; 2004 Jan; 108(3):443-9. PubMed ID: 14648712
[TBL] [Abstract][Full Text] [Related]
25. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.
Martínez-Calle N; Alfonso A; Rifón J; Herrero I; Errasti P; Rábago G; Merino J; Panizo Á; Pardo J; Prósper F; García-Muñoz R; Lecumberri R; Panizo C
Eur J Haematol; 2017 Jan; 98(1):38-43. PubMed ID: 27232286
[TBL] [Abstract][Full Text] [Related]
26. Post-transplant lymphoproliferative disorders with naso- and oropharyngeal manifestation.
Akbas A; Tiede C; Lemound J; Maecker-Kolhoff B; Kreipe H; Hussein K
Transpl Int; 2015 Nov; 28(11):1299-307. PubMed ID: 26147593
[TBL] [Abstract][Full Text] [Related]
27. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression.
Ichikawa A; Arakawa F; Kiyasu J; Sato K; Miyoshi H; Niino D; Kimura Y; Takeuchi M; Yoshida M; Ishibashi Y; Nakashima S; Sugita Y; Miura O; Ohshima K
Eur J Haematol; 2013 Jul; 91(1):20-8. PubMed ID: 23560463
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological categorization of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disease: an analysis of 42 cases with an emphasis on prognostic implications.
Paik JH; Choe JY; Kim H; Lee JO; Kang HJ; Shin HY; Lee DS; Heo DS; Kim CW; Cho KH; Kim TM; Jeon YK
Leuk Lymphoma; 2017 Jan; 58(1):53-63. PubMed ID: 27157296
[TBL] [Abstract][Full Text] [Related]
29. The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.
Takanashi S; Nakazato T; Aisa Y; Ito C; Arakaki H; Osada Y; Hirano M; Mori T
Ann Hematol; 2018 Sep; 97(9):1611-1618. PubMed ID: 29713747
[TBL] [Abstract][Full Text] [Related]
30. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication.
Hoshida Y; Xu JX; Fujita S; Nakamichi I; Ikeda J; Tomita Y; Nakatsuka S; Tamaru J; Iizuka A; Takeuchi T; Aozasa K
J Rheumatol; 2007 Feb; 34(2):322-31. PubMed ID: 17117491
[TBL] [Abstract][Full Text] [Related]
31. [Inherited lymphoproliferative disorders].
Kanegane H; Hoshino A
Rinsho Ketsueki; 2019; 60(6):708-715. PubMed ID: 31281164
[TBL] [Abstract][Full Text] [Related]
32. Primary immunodeficiency diseases and Epstein-Barr virus-induced lymphoproliferative disorders.
Okano M; Nakanishi M; Taguchi Y; Sakiyama Y; Matsumoto S
Acta Paediatr Jpn; 1992 Aug; 34(4):385-92. PubMed ID: 1329432
[TBL] [Abstract][Full Text] [Related]
33. Posttransplant lymphoproliferative disorder after liver and kidney transplant.
Akar Özkan E; Özdemir BH; Deniz EE; Tunca MZ; Haberal M
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():142-8. PubMed ID: 24635813
[TBL] [Abstract][Full Text] [Related]
34. CD30 expression and survival in posttransplant lymphoproliferative disorders.
Kinch A; Amini RM; Hollander P; Molin D; Sundström C; Enblad G
Acta Oncol; 2020 Jun; 59(6):673-680. PubMed ID: 32102582
[No Abstract] [Full Text] [Related]
35. Clinical aspects in patients with rheumatoid arthritis complicated with lymphoproliferative disorders without regression after methotrexate withdrawal and treatment for arthritis after regression of lymphoproliferative disorders.
Nakano K; Saito K; Nawata A; Hanami K; Kubo S; Miyagawa I; Fujino Y; Nakayamada S; Tanaka Y
Mod Rheumatol; 2021 Jan; 31(1):94-100. PubMed ID: 32159414
[TBL] [Abstract][Full Text] [Related]
36. Array-CGH predicts prognosis in plasma cell post-transplantation lymphoproliferative disorders.
Sarkozy C; Kaltenbach S; Faurie P; Canioni D; Berger F; Traverse-Glehen A; Ghesquieres H; Salles G; Bachy E; Alyanakian MA; Hermine O; Neven B; Macintyre E; Romana S; Molina TJ; Suarez F; Asnafi V; Bruneau J
Genes Chromosomes Cancer; 2017 Mar; 56(3):221-230. PubMed ID: 27750397
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow involvement by lymphoproliferative disorders after solid-organ transplant.
Akar Özkan E; Özdemir BH; Yılmaz Akçay E; Terzi A; Karakuş S; Haberal M
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():183-7. PubMed ID: 25894151
[TBL] [Abstract][Full Text] [Related]
38. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
Tokuhira M; Tanaka Y; Takahashi Y; Kimura Y; Tomikawa T; Anan T; Watanabe J; Sagawa M; Higashi M; Momose S; Amano K; Tabayashi T; Nakaseko R; Tamaru JI; Kizaki M
J Clin Exp Hematop; 2020 Jun; 60(2):41-50. PubMed ID: 32404570
[TBL] [Abstract][Full Text] [Related]
39. Posttransplant Lymphoproliferative Disorders in Irish Renal Transplant Recipients: Insights From a National Observational Study.
OʼRegan JA; Prendeville S; McCaughan JA; Traynor C; OʼBrien FJ; Ward FL; OʼDonovan D; Kennedy C; Berzan E; Kinsella S; Williams Y; OʼKelly P; Deady S; Comber H; Leader M; Conlon PJ
Transplantation; 2017 Mar; 101(3):657-663. PubMed ID: 27214265
[TBL] [Abstract][Full Text] [Related]
40. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate.
Saito S; Kaneko Y; Yamaoka K; Tokuhira M; Takeuchi T
Rheumatology (Oxford); 2017 Jun; 56(6):940-946. PubMed ID: 28165538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
